Does the FDA guidance affect perimenopause care

DISCLOSURE: Voshell’s Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

The short answer is: No, recent FDA guidance does not restrict or reduce access to standard, commercially available hormone therapy for perimenopause. It mainly clarifies safety expectations for hormone products and does not change how clinicians prescribe HRT for symptoms.

How FDA guidance fits into perimenopause care

According to FDA.gov, the FDA’s role is to ensure that hormone products sold in the U.S. are well-studied, consistent, and subject to safety monitoring. Their guidance addresses how hormones must be tested, labeled, and monitored. This applies to estrogen and progesterone used during perimenopause, but it does not limit your ability to receive treatment. It reinforces standards intended to protect patients.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Here is what it means in real life:

• Commercially available hormones remain the first-line option: According to FDA-approved prescribing information, products such as estradiol patches, gels, creams, and micronized progesterone capsules are available for perimenopause symptoms including hot flashes, night sweats, sleep changes, and cycle instability.
• Dosing stays individualized: According to ACOG, the guidance does not require a “one-size-fits-all” plan. A qualified prescriber may still adjust dose, route, and timing based on symptoms, age, cycle pattern, and individual risk factors.
• No ban on HRT: According to FDA.gov, estrogen and progesterone for perimenopause remain available for appropriate candidates when initiated at the correct dose and monitored by a qualified prescriber.
• Compounded hormone products receive additional scrutiny: According to FDA Drug Safety Communication, the FDA reminds clinicians that compounded hormones are not evaluated for purity or consistency prior to dispensing. This applies separately from patients using commercially available estradiol and progesterone products.
• Safety guidance clarifies known risk considerations: According to the FDA-approved prescribing information, the FDA restates established points: use the lowest effective dose, check for contraindications, and combine systemic estrogen with progesterone in patients with an intact uterus. None of this is new, and none of it blocks access to treatment.

How this affects your perimenopause choices

According to NAMS, patients may begin hormone therapy during perimenopause when a qualified prescriber determines it fits the individual’s symptoms and health profile. FDA guidance does not change when hormone therapy may be initiated, which hormones are used, or how long they may be continued. It ensures that the products patients receive are subject to pre-market review, consistency requirements, and post-market safety monitoring.

The bottom line: FDA guidance supports informed perimenopause care by clarifying product safety standards; it does not restrict access to commercially available hormone therapy. Decisions about treatment remain the responsibility of a qualified prescriber.